Consumer group, 503B firm book White House peptide meetings

Forwarded this? Get it weekday mornings: optimized.news/subscribe

Take. Every protection added to FDA's peptide plan is a cost someone pays. Large pharmacies can spread that cost over volume. Smaller ones will pass it on, so we expect fewer pharmacy partners and higher prices for clinics. The telehealth brands that already pay compliance teams gain ground. We wouldn't lock in next year's peptide pricing until FDA publishes the plan.

Bloomberg Law reported Thursday that the version under White House review "includes more patient protections than initially expected, according to people familiar with the matter." Its headline says the plan makes compounders report side effects. FDA sent it to the White House as a notice-stage Interim Access Policy, not a rule.

Two more groups have booked time with White House reviewers, per OIRA's meeting log. That makes five. The Center for Science in the Public Interest, a consumer advocacy group, meets next Tuesday at 2:30 p.m. Lobbying firm Carmen Group meets next Wednesday at 3:30 p.m. for Medivant Healthcare. Medivant calls itself an FDA-registered 503B outsourcing facility. The American Academy of Peptide Medicine, Hims & Hers and the Alliance for Pharmacy Compounding were already on the list. No meeting materials have posted.

CSPI has said where it stands. Last week it asked FDA to overrule July's advisory committee votes that recommended six of seven peptides for the 503A bulks list. Its letter notes FDA staff scientists had said all seven should "NOT be included." CSPI counted 18 instances where committee members cited reasons outside FDA's four listing criteria, including "medical freedom." The votes were recommendations. The bulks list itself is unchanged.

Medivant's slot puts 503B on the calendar. Outsourcing facilities can make drugs in batches without a prescription for each patient. Whether the plan reaches 503B at all is the scope question to read first when FDA publishes it.

FDA issued final guidance Tuesday on apps that drug companies give patients to use with a prescription drug, such as a dose tracker or an autoinjector app. Coverage turns on who distributes the app. The guidance covers software "disseminated by or on behalf of a drug sponsor," including a developer "working under an agreement with the drug company." FDA treats what those apps show patients as drug labeling. Most of it counts as promotional labeling, filed with FDA on Form 2253 when it first goes out. The form even has a new "PDURS" material type. An app with no tie to a drug company is outside the guidance, though device rules can still apply. The text says nothing about compounded drugs, pharmacies or telehealth. The exposure is in brand partnerships. A telehealth platform that builds or links an app under a manufacturer agreement could fall inside it. Expect brand partners to write that review work into vendor contracts. The guidance is nonbinding and has no effective date.

The Partnership for Safe Medicines filed a citizen petition asking FDA not to allow compounding of the seven peptides from July's advisory committee, including BPC-157 and TB-500. It lists every route, from a rule to enforcement discretion. The group also argues the committee was formed in violation of federal ethics and advisory-committee law. A citizen petition is a formal request. FDA decides whether to grant it.

Fresha runs booking and payments software for salons, spas and other beauty and wellness businesses. Its lending arm, built with payments company Adyen, has issued more than $20 million in loans to 1,546 providers since launching early this year, the company says. Offers average about 65% of a business's monthly takings. More than 80% of borrowers came back for another loan. Your booking software already sees your card volume. That makes it a lender that already knows your revenue.

If this was useful, forward it to a colleague. Hit reply to tell us what you'd like to see more of.

Follow us on X: @optimizednews

Follow ODR on LinkedIn

Optimized Daily Report is business news for clinic operators. Not medical, legal, or investment advice. Company claims are the company's.